Peptides for Hormonal Symptom Control
Reviewed by Marcus Hopkin, PhD
Director of Research and Development, Volta Peptides
Written by Volta Peptides Editorial Team · Reviewed September 15, 2026
This guide explores two peptides that have garnered attention in the realm of hormonal symptom control, offering a comprehensive overview of their mechanisms, clinical status, and safety profiles. These peptides are assessed based on the strength of available evidence, ranging from FDA-approved compounds to those in early preclinical stages. By evaluating their pharmacological actions and therapeutic implications, this resource aims to provide clarity on their role in managing hormonal symptoms effectively.
Overview
2 research peptides are currently studied for hormonal symptom control. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
Octreotide — FDA Approved
Lanreotide, another somatostatin analog, operates through a unique mechanism of self-assembly into nanotubes at high concentrations, facilitating sustained drug release over an extended period—up to four weeks—following a single injection. This property enhances patient compliance by reducing the frequency of administration. Clinical studies have demonstrated that lanreotide effectively controls GH and IGF-1 levels in patients with acromegaly, similar to octreotide. Furthermore, it has shown promise in extending progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), highlighting its potential as a therapeutic option in oncology. While lanreotide is FDA-approved and recognized for its therapeutic benefits, researchers continue to explore its long-term safety and efficacy in diverse populations, particularly in relation to its impact on tumor growth and metabolic parameters.
Lanreotide — FDA Approved
Evidence Rating: A
Category: Endocrine / Somatostatin Analog
Lanreotide self-assembles into nanotubes at high concentration, enabling sustained drug release over 4 weeks from a single injection.
Key claims: Controls GH and IGF-1 in acromegaly; Extends progression-free survival in GEP-NETs.
Shop Research Peptides
Cagrilintide 5mg
DSIP 10mg
Epithalon 10mg
GHRP-2 5mg
5mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Peptide Tools
Key research references
- Best Peptides for Anti-Aging | Research Guide
- Best Peptides for Metabolic Health | Research Guide
- Best Peptides for Weight Management | Research Guide
- Best Peptides for Body Composition | Research Guide
- Best Peptides for Reproductive Health | Research Guide
- Best Peptides for Anti-Aging & Longevity | Research Guide
- Best Peptides for Weight Loss | Research Guide
- Best Peptides for Cognitive Enhancement | Research Guide
- Retatrutide Dosing Guide | Protocols & Reconstitution
- Wound Healing Peptides | Research Compounds
- Muscle Growth Peptides | Research Compounds
- Immune Modulation Peptides | Research Compounds
Browse the research catalogue
Buying and verification
Frequently Asked Questions
Related Resources
Related Research
About the reviewer
Director of Research and Development, Volta Peptides
Marcus Hopkin, PhD, is Director of Research and Development at Volta Peptides. He has more than 12 years of analytical chemistry experience, including direct laboratory work in peptide synthesis, characterization, purity testing and stability assessment. His doctoral research at the University of Michigan examined novel peptide structures in the human proteome and their potential significance for therapeutic-peptide research. Before joining Volta Peptides he held research and development roles at Amgen and Eli Lilly and Company, and served as a lecturer at the University of Michigan.
Marcus reviewed this article for scientific and analytical accuracy on September 15, 2026. He did not write it. Technical review is internal review and is not peer review, independent third-party review or medical review.
Disclosure. Marcus Hopkin is an employee of Volta Peptides and serves as its Director of Research and Development. Volta Peptides sells research compounds related to subjects discussed in the content he writes and reviews. His reviews are internal scientific and technical review and must not be described as independent third-party review, peer review or medical review.